C-8M5WGlyscend
gut-targeted polymers, dynamic barrier, metabolic surgery mimicry
modulatingdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8M5W
C-8M5WC-8M5Wgut-targeted polymers, dynamic barrier, metabolic surgery mimicry
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.
This study is a Phase 2, randomized, double-blind, placebo-controlled, single-center study in adult patients with type 2 diabetes. It will evaluate the safety and tolerability of oral GLY-200. Subjects will participate in a ≤ 18-day screening period followed by a metformin washout period of approximately 14 days, and an inpatient period of 16 days. Approximately 48 subjects will be randomized to 1 of 3 active treatment groups or 1 of 3 placebo groups. Dosing will occur for 14 days. A follow-up clinic visit will occur on Day 21 \[End of Study (EOS)\] or Early Termination (ET).
Glyscend’s First-in-Class Oral Diabetes Drug Shows Phase II Promise - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Glyscend’s First-in-Class Oral Diabetes Drug Shows Phase II Promise May 31, 2023 | 3 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Pictured: Pills spilling out from a yellow contain Bet_Noire/Getty Images/iStockphoto The company’s oral gut-targeting pol … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy August 4, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual me … and Australia’s Brandon Capital through its Medical Research Commercialization Fund (MRCF) with support from Breakout Labs, a fund in the Thiel Foundation. About Glyscend, Inc. Glyscend Therapeutics is a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D. Glyscend’s polymer technology platform evolved from research at Johns Hopkins University, w … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease June 3, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Glyscend Therapeutics today announced the initiation of a Phase 2 c … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
People articles and careers information on BioSpace Skip to main content Skip to main menu Skip to user menu Jobseeker Sign in News Drug Development FDA Drug Delivery Deals Business Policy Cell and Gene Therapy Weight Loss Rare Disease Cancer Job Trends Artificial Intelligence NextGen: Top Start Ups To Watch Podcasts Reports Webinars Press Releases All News & Releases Insights Jobs Search Jobs Job Alerts Jobseeker Sign In Career Advice Companies Hotbeds More Best Places to Work Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release Subscribe Subscribe Search Jobs Job Al … Fridriksdottir is stepping down following resubmission of the Biologics License Application for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira®. Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer 9/5/2023 Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, including obesity and type 2 diabetes, with first-in-clas … icy More Employer Login Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release RSS Feeds Facebook This will open in a new window Twitter This will open in a new window LinkedIn This will open in a new window Instagram This will open in a new window © 1985 - 2026 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment May 11, 2022 | 7 min read Twitter LinkedIn Facebook Email Print Glyscend Therapeutics, a clinical-stage biotechnolog … only common adverse events observed. Based on these findings, Glyscend plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration and begin Phase 2 development in patients with T2D in mid-2022. Dr. Fineman added, “The GI tract has long been recognized as a major player in metabolic regulation due to its role in modulating signaling between the gut, liver, and brain. At Glyscend, we have curated an expansive library of novel non-abso … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer September 5, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors March 30, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Deve … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity May 31, 2023 | 8 min read Twitter LinkedIn Facebook Email Print Glyscend Therapeutics, a clinical-stage biotechnology compan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes June 11, 2020 | 8 min read Twitter LinkedIn Facebook Email Print –Patient-Friendly Therapy Designed to Mimic the Dramatic Metabolic Benefits of Bariatric Surgery – –Company Aims to Begin First-in-H … stors Brandon Capital Partners , through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures led the round of funding, which will be used to support the development of the company’s novel oral polymer therapy for patients with T2D and other metabolic diseases. Breakout Labs (a fund in the Thiel Foundation) provided seed funding in 2019. “The technology we are developing was inspired by the remarkable efficacy of gastric bypass surgery in correcting the … com . About Brandon Capital Partners and the Medical Research Commercialisation Fund (MRCF) Headquartered in Melbourne, Australia, Brandon Capital Partners is a venture capital firm that manages the Medical Research Commercialisation Fund (MRCF), Australia and New Zealand’s largest life science investment fund. The MRCF is a unique collaboration between major Australian pension funds, the Australian and New Zealand governments, Australian state governments and more than 50 le … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Andrew Eckert – Page 26 – BioHealth Capital Region Home BHCR Forum BHCR Forum 2024 BHCR Forum 2023 BHCR Forum 2022 BHCR Forum 2021 BHCR Forum 2020 BHCR Forum 2019 Investment Conference Contact Press enter to begin your search No menu assigned! All Posts By Andrew Eckert Jun 11 0 Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes By Andrew Eckert | News | No Comments –Patient-Friendly Therapy Designed to Mimic the Dramatic Metabolic Benefits of Bariatric Surgery – –Company Aims to Begin First-in-Human Trials in Australia … stors Brandon Capital Partners , through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures led the round of funding, which will be used to support the development of the company’s novel oral polymer therapy for patients with T2D and other metabolic diseases. Breakout Labs (a fund in the Thiel Foundation) provided seed funding in 2019. “The technology we are developing was inspired by the remarkable efficacy of gastric bypass surgery in correcting the meta … com . About Brandon Capital Partners and the Medical Research Commercialisation Fund (MRCF) Headquartered in Melbourne, Australia, Brandon Capital Partners is a venture capital firm that manages the Medical Research Commercialisation Fund (MRCF), Australia and New Zealand’s largest life science investment fund. The MRCF is a unique collaboration between major Australian pension funds, the Australian and New Zealand governments, Australian state governments and more than 50 le … y investment experts from Alexandria Venture Investments, The BioHealth Capital Fund, Boston Millennia Partners, and JP Morgan. Collaborating for Growth in the BioHealth Capital Region Being able to collaborate with your business partners is as important today as it ever has been. This panel demonstrates the strong collaboration taking place in the BioHealth Capital Region. Led by Jarrod Borkat, Senior Director, External Partnerships & Collaborations, Emergent BioSolution … nference Registration on June 8-10, 2020 ONLINE. May 28 0 USM Maryland Momentum Fund Invests $150,000 in pathOtrak By Andrew Eckert | News | No Comments Company led by Former UMCP and National Institute of Standards and Technology Faculty Member Drastically Cuts Detection Time for Salmonella and E. coli in Food The University System of Maryland (
Newsroom - Santé Skip to content Main Menu About Portfolio Team Newsroom Contact News Here's the latest news from Santé and its portfolio companies Portfolio Sonire Therapeutics Completes Enrollment in SUNRISE-I Randomized Controlled Trial of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer June 3, 2026 Portfolio KēlaHealth Raises $12.9M in Combined Seed and Series A Financing Round to Deliver AI-Powered, Clinician-Centered Solutions That Improve Surgical Care November 2, 2020 Uncategorized Hello world! October 15, 2020 Portfolio Libra Therapeutics Launches with $29 Million Series A to Dev
Innovative type two diabetes treatment scores $29m Skip to navigation Skip to content Skip to footer Help using this website - Accessibility statement Today's Paper Today's Paper Markets Data Events Lists The Australian Financial Review Menu Search Newsfeed Newsfeed Home Companies Financial Services Mining Professional Services Retail Telecommunications Energy Healthcare & Fitness Infrastructure Transport Media & Marketing Gaming & Wagering Manufacturing Agriculture Sport Tourism Markets Equity markets Commodities Currencies Debt markets Private markets Markets Live Marke … n cash injection from Brandon Capital's Medical Research Commercialisation Fund and US fund Santé Ventures. Brandon Capital investment manager and Glyscend director Dr Bob Soh says diabetes is a major burden on the healthcare system. Chris Hopkins Loading... Save Log in or Subscribe to save article Share Copy link Copied Email LinkedIn Twitter Facebook Copy link Copied Share via... Gift this article Subscribe to gift this article Gift 5 articles to anyone you choose each … inum Year Contact Contact Support Letters to the editor Freelance Contributions Submit a story Advertise Delivery Status Magazines Magazines AFR Magazine Fin! Magazine BOSS Life & Leisure Columns Columns Chanticleer Street Talk Rear Window The AFR View Podcasts Podcasts 15 Minutes with the Boss Chanticleer Tech Zero The Fin The Sure Thing How I Made It Markets Data Markets Data Australian Indices World Indices Commodities Bonds & Currencies Companies index Lists Lists
--> Glyscend study reveals metabolic benefits of its oral polymer-based duodenal exclusion therapy top of page Latest All News Podcast Events Directory Contact More Use tab to navigate through the menu items. Subscribe Thanks for submitting! All Posts All News Research Spotlight Industry & Products Events & Training Journal watch Surgery News Latest News Top 10 obesity paradox metabolic and bariatric surgery Obesity treatment in the UK bariatric surgery utilisation -1 utilisation Search Glyscend study reveals metabolic benefits of its oral polymer-based duodenal exclusion therapy owenh
Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy – Brandon BioCatalyst Toggle navigation About us Our story Members Board Investors Government Partners Membership Benefits Investment Process Investments Training Biotech Innovators Program Cicada x Brandon BioCatalyst at Westmead Brandon BioCatalyst Internship Queensland TACSGP Women in Leadership Development (WILD) CUREator About Programs Process and Investment Review Committee Portfol … and Australia’s Brandon Capital through its Medical Research Commercialization Fund (MRCF) with support from Breakout Labs, a fund in the Thiel Foundation. ENDS About Glyscend, Inc. Glyscend Therapeutics is a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D. Glyscend’s polymer technology platform evolved from research at Johns Hopkins Universi
You need to enable JavaScript to run this app. Loading...
Australia’s Brandon Capital leads AU$29 M series A investment in Glyscend’s diabetes polymer compound | 2020-07-17 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 revi
Glyscend reports new phase 1 biomarker results for diabetes drug Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Brow … U.S. Food and Drug Administration (FDA) on an Investigational New Drug ( IND ) application to evaluate GLY-200 for the treatment of T2D and has initiated a phase 2 clinical trial in patients with the condition. Glyscend says that metabolic surgery is a highly effective but invasive treatment for T2D and works in part by excluding the duodenum (the upper small intestine) from the digestive tract. GLY-200 is taken orally and is designed to mimic this duodenal exclusion by enha … nitiation of the phase 2 trial follows FDA clearance of the company’s IND application for GLY-200 for T2D. Glyscend’s CEO, Ashish Nimgaonkar, said: “We are thrilled to have expeditiously advanced GLY-200 into the Phase 2 trial in patients with T2D. Type 2 diabetes remains a dangerous, growing, and expensive endemic worldwide, with a severe lack of pharmaceutical innovation over the last 15 years. Accelerated timelines “The U.S. FDA’s recently revised guidance that
SABPA Membership Management and Event Registration Sign In Sign Up Help Home Events News Careers Sponsors SABPA SD Sponsors SABPA OCLA Sponsors Donations Vote About SABPA Newsletter All News SABPA Newsletter April 2024 April 1, 2024 SABPA is pleased to present you the following in this newsletter: 1. The 8th Frontiers in Therapeutics & Diagnostics Forum Recap 2. BioCentury SoCal Biotech & Venture Networking Reception 3. Community News 1. The 8th Frontiers in Therapeutics & Diagnostics Forum Recap The 8th Annual Frontiers in Therapeutics & Diagnostics Forum (FTD Forum), one of t … d the morning sessions. In the morning sessions, the 2024 SAPBA FTD Achievement Award recipient, Chief Scientific Advisor of Novo Nordisk Lotte Bjerre Knudsen, highlighted the broad applications of GLP-1 receptor agonists in treating diabetes, obesity, and cardiovascular diseases. Mark Fineman, PhD, and Chief Development Officer of Glyscend Therapeutics shared the history of Glyscend’s First-in-Class GLP-1 Receptor Agonist. William Roll, PhD, Director, Insulin Discovery/Incre … California’s Biotech and Pharmaceutical communities. 2024 SABPA FTD Achievement Award Hua / Lotte / Steph Lotte Bjerre Knudsen The Panelists ] 2. BioCentury SoCal Biotech & Venture Networking Reception In conjunction with the 2024 BIO Conference, SABPA and BioCentury are pleased to co-host a networking reception showcasing biotech and venture in Southern California. Join the fireside chat with David Crean and Karen Tuzman for their insights on the investment environment and t … d small molecule inhibitor. Subject to Kumquat's option, Takeda will assume and fund all development and commercialization activities beyond the phase 1 trial activities led by Kumquat. Kumquat will receive up to $130 million in near-term payments and potentially more than $1.2 billion if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement plus tiered royalties on potential net sales of any commercial products resulting fro
Portfolio details | NSF SBIR Skip to main content An official website of the United States government. For proposal preparation and submission instructions, click here . The SBIR/STTR program looks forward to receiving the submission of new Project Pitches in response to the new solicitations beginning on Tuesday, June 2, 2026. Please direct any questions to [email protected] . --> Menu About Our Program Contact Critical Information How It Works Get Started Project Fit Assessment Project Pitch Full Proposal Proposal Review & Decision What We Fund Funding Topic Areas Award Search Resources Solicitat … ortfolio Featured Companies In Partnership with CEP In the News Showcase Search Award Details There were no results found for that query . Try a new search or return to previous page to try again. Search America's Seed Fund awardees Loading company results... Phase II 4 D Technology Corporation SBIR Phase II: High-Resolution Shop Floor Video-Rate Surface Metrology System Project Leader Erik Novak (520) 294-5600 Principal Investigator Contact 3280 E Hemisphere Loop, Ste 146 Tu … Investigator Contact 3280 E Hemisphere Loop, Ste 146 Tucson, AZ 85706-5024 NSF Award 1556049 – SBIR Phase II Award amount to date $1,348,048 Start / end date 03/01/2016 – 09/30/2019 Errata Please report errors in award information by writing to [email protected] . Abstract This Small Business Innovation Research (SBIR) Phase II project will develop and produce a robust, hand-held, video-rate three-dimensional surface metrology system with vertical and lateral resolution of … 8 Principal Investigator Contact 2804 Glen Burnie Dr Raleigh, NC 27607-3009 NSF Award 1758659 – SBIR Phase II Award amount to date $909,999 Start / end date 02/01/2018 – 06/30/2021 Errata Please report errors in award information by writing to [email protected] . Abstract The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project has the potential to help enhance disease resistance in poultry and increase yields due to the del … imaging technologies for the use of screening and targeting live animals. This proposal brings innovation in the care of food animals allowing for producers to move away from flock health and focus on the care of individual animals. This will be a dramatic change for the poultry industry, but is necessary in the face of antibiotic removal to be
Glyscend Therapeutics: simplifying treatments for type 2 diabetes Skip to content VentureWell Menu search Search for: cancel students & startups Funding & Training The VentureWell Accelerator E-Team Program: Pioneer and Propel Ascend Aspire VentureWell Ocean Enterprise Accelerator FLIPspace American-Made Solar Prize Round 8 NSF I-Corps™ DEBUT GIST Learning & Impact Podcast Venture Development Framework Our Investment Portfolio Meet Our Innovator Teams Events & Opportunities faculty & institutions Faculty & Staff Initiatives Ecosystem Futures Fellowship FLIPspace E … eWell, the team learned of the NSF’s I-Corps program, which in turn helped them apply for and receive other large grants. a pivot to a polymer But in early development of the patch concept, some flaws emerged. “We had some difficulty with reducing that concept to practice,” Colbert recalls. “Very practical considerations, like, how do you get the patches to not stick to one another once they are released from the capsule? And how do you ensure that you’re getting suffic … ion that we were on the right path, and it was also tied to a helpful financial grant,” he explains. “Early on, when Glyscend was entirely grant-funded, we were constantly looking to win the next grant or award in order to extend our runway. Each win would provide opportunity to ramp up company research and operations, which would in turn provide the ammunition for the next grant application, and the cycle continued. VentureWell plays a really important role in that early-sta … for its current success. “The tenets of VentureWell, in terms of the training, grant funding, and the networking, are valuable collectively,” Colbert says. “I am very much in favor of that model. Not every grant or award that we won had all three, and especially for early-stage companies, the combination is invaluable.” Learn more about innovators we’ve supported over the last 25 years : HandHero: life after a startup AeroShield Materials: building a greener window Sen
News - Glyscend Skip to main content Hit enter to search or ESC to close Close Search Menu Home About Corporate Overview Boards Science Scientific Overview MCP Platform Publications Clinical Trials News Press Releases News Features Contact Glyscend in the news Press releases 2024 2023 2022 2021 2020 Press Release | June 3, 2024 Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease B oston, MA (June 3, 2024) – Glyscend Therapeutics… today announced the initiation of a Phase 2 clinical trial … he U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to… LEARN MORE Press Release | May 11, 2022 Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment B oston, MA and Baltimore, MD (May 11, 2022) – Glyscend reported the completion of a Phase 1 trial for its lead clinical-stage program, GLY-200, as a treatment for type … ound Glyscend… LEARN MORE TedCo | May 2017 Glyscend wins TEDCO's 2017 ICE Award for Innovation in Baltimore The Maryland Technology Development Corporation (TEDCO) today hosted the organization’s seventh annual ICE Awards. Held at the Columbus Center (IMET) in Baltimore, Md., the awards program recognized outstanding businesses and individuals from TEDCO’s diverse portfolio of more than 300 seed and early-stage companies… LEARN MORE Johnson-Johnson | January 2017 … MORE Baltimore Business Journal | November 2016 Baltimore startup wins $500,000 grant from Johnson & Johnson Baltimore-based Glyscend Inc. was awarded one of three $500,000 research grants from Johnson & Johnson Innovation LLC and its research arm Janssen as part of the health care giant’s World Without Disease QuickFire Challenge… LEARN MORE Glu | October 2016 Glyscend places 2nd in the T1D Exchange/M2D2 Diabetes Innovation Challenge in Boston, MA. The ex … ational Scientific Foundation (NSF) | July 2015 Glyscend wins $225,000 NSF STTR Grant in partnership with Johns Hopkins University The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop the first non-invasive, device-based treatment for type 2 diabetes which mimics the therapeutic b
Glyscend, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Glyscend, Inc. Startups | Holding Company | 2014 | Maryland, United States | < 10 | www.glyscend.com Startups | Holding Company | 2014 | Maryland, United States | < 10 | www.glyscend.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Endocrinology and Metabolic Disease Biological products Disease domain score A glimpse into the focused therapeutic area … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Home - Glyscend Skip to main content Hit enter to search or ESC to close Close Search Menu Home About Corporate Overview Boards Science Scientific Overview MCP Platform Publications Clinical Trials News Press Releases News Features Contact An innovative approach to the treatment of Type 2 Diabetes and Obesity A novel class of gut-targeted polymer therapies The benefits of metabolic surgery without the risks Mimicking the effect of bariatric surgery with an oral pill Glyscend’s dynamic barrier approach seeks to provide the benefits of gastric bypass sur
Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer - Santé Skip to content Main Menu About Portfolio Team Newsroom Contact News Share Portfolio Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer September 6, 2023 Planned Leadership Transition to Accelerate the Company’s Next Stage of Growth; Founding CEO Ashish Nimgaonkar, M.D., Transitions to Chief Medical Officer and Head of R&D Lead Candidate, GLY-200, Ready to Begin Phase 2b Development for Obesity and Type 2 Diab
About Us - Glyscend Skip to main content Hit enter to search or ESC to close Close Search Menu Home About Corporate Overview Boards Science Scientific Overview MCP Platform Publications Clinical Trials News Press Releases News Features Contact Pioneering a new generation of gut-targeted polymer therapies Corporate Overview Glyscend Therapeutics is a venture-backed, clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. The company evolved from the founding team’s research on how certain types of bariatric surgeries lead to significan